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This paper details the substance and recommendations arising from a meeting convened by the National Heart,
Lung, and Blood Institute in August 2009, to assess the challenges and opportunities of emergency department
management of acute heart failure syndrome (AHFS). The assembled faculty represented a large cross section
of medical professionals spanning the medical management continuum of patients presenting with acute heart
failure and included heart failure cardiologists, emergency physicians, laboratory medicine specialists, nurses,
and bench scientists. Their recommendations include proposals regarding the design and conduct of emergency
department-based clinical trials, suggestions regarding the development of improved methods for early detec-
tion and monitoring of AHFS, and potential needs for expanding translational and applied AHFS focused re-
search and biotechnology. We anticipate that this review will serve as a starting point for future investigations
across the spectrum of funding sources. (J Am Coll Cardiol 2010;56:343–51) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.051d
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Mll participants agreed that there is a critical need for
vidence based management of acute heart failure syndrome
AHFS) in the emergency department (ED). Of 18 Class I
ecommendations for AHFS treatment, only 1 has Level of
vidence: A data (1). Most AHFS therapies are based on
xpert opinion (Level of Evidence: C). Furthermore, new
herapies/technologies have failed to improve survival or
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NHLBI Acute Heart Failure Emergency Department Workshop July 27, 2010:343–51higher-risk patients who require
hospital admission to an inten-
sive care unit (ICU) in the most
severe cases; and 2) that early car-
diac and noncardiac (particularly
renal) injuries require a better basic
understanding of the pathophysi-
ologic contributions and potential
therapeutic responses. There was
optimism that new diagnostic and
therapeutic strategies could be life-
aving if applied during the appropriate time window in the
D and followed by appropriate post-ED management.
Future therapeutic interventions will come from: 1) the
asic cardiovascular sciences, including molecular medicine
nd pharmacology; 2) better understanding of AHFS phe-
otypes; and 3) the development of new diagnostic tech-
iques and technologic advances. Novel AHFS targeted
herapies will require careful testing with study designs
ocused on timing, route of administration, and co-
dministration of complementary therapies. This will need
ollaboration among basic scientists, bioengineers, and di-
erse clinical disciplines, such as emergency medicine, car-
iology, hospital medicine, and critical care.
Recommended actions include:
. Design and conduct ED based clinical trials. These
should focus on emergency AHFS management and
should include prospective testing of both existing and
new interventions in specifically targeted groups. For
optimal conduct, there is a need for coordinated proto-
cols and data management as well as the development of
consensus on therapeutic end points and outcomes.
Research priorities for funding were recommended,
including: 1) biomarkers for early diagnosis and manage-
ment; 2) early aggressive versus conservative man-
agement of congestion; 3) initial versus delayed ma-
nipulation of the neurohormonal system; and 4) the
discharge strategy of patients after the ED. New initia-
tives should explore differences among patients across a
wide range of ages, sexes, and racial/ethnic populations
while focusing on the need to understand the pathophys-
iology of different syndromes.
. Develop improved methods for early detection and
monitoring of AHFS. These should consider the devel-
opment and testing of currently available biosensors to
monitor physiologic data guiding interventions in “real
time.” The development of new technologies is likely to
require collaboration between basic and clinical scientists
as well as between academia and industry.
. Expand translational and applied AHFS focused re-
search and biotechnology. These should include collab-
orative research uniting basic and applied scientists
targeting mechanisms of cellular, organ, and systems
injury in AHFS. Special areas of interest include: 1) gene
Abbreviations
and Acronyms
AHFS  acute heart failure
syndrome
ED  emergency
department
HF  heart failure
NP  natriuretic peptide
OU  observation unitexpression variation, induction, and regulation in AHFS cwith a focus on identifying opportunities for early man-
agement; 2) the role of the vasculature in AHFS;
3) targeting the kidney with approaches that might
protect renal function and enhance the early relief of
circulatory congestion; 4) novel approaches for modulat-
ing neurohormonal activation; and 5) early introduction
of therapies that mitigate progressive cardiac dysfunction
and prevent recurrence of AHFS episodes. The latter
includes the evaluation of the early use of older inter-
ventions (e.g., the use of digoxin for AHFS patients with
predominant systolic heart failure [HF]).
D Management of AHFS:
hallenges and Opportunities
pidemiology. There are an estimated 3,000,000 annual
ospital stays for primary or secondary HF, of which
pproximately 80% initially present to the ED (2,3). Hos-
italized HF patients are a heterogeneous group with a wide
ange of 30-day mortality (1.7% to 7.2%) and a high
ost-discharge event rate, approaching 40% at 90 days in
ome cohorts (4). In fact, HF has the highest readmission
ate of any discharge diagnosis.
Acute heart failure syndrome represents a complex, het-
rogeneous set of clinical conditions with the common
enominators of pulmonary congestion and dyspnea. Be-
ause most AHFS patients present to the ED with normal
r increased blood pressure (only 5% have a systolic blood
ressure 90 mm Hg), most receive loop diuretic agents.
lthough these are reasonably effective at addressing con-
estion, a number of poorly understood pathophysiologic
hanges might be more appropriately managed by therapies
argeting alterations in hemodynamic, neurohormonal, and
ndothelial function, as well as myocyte viability, function,
nd ischemia. The importance of renal deterioration, often
s a result of aggressive dieresis, must be emphasized,
ecause worsening renal function is 1 of the most powerful
redictors of prognosis. Which specific interventions repre-
ent optimal therapy will only be determined after these
linical profiles are studied prospectively.
Currently, there are few high-quality data guiding clinical
ecision-making. Future trials should distinguish the ap-
roach to treatment on the basis of the HF profile. This is
nalogous to the treatment of ST-segment elevated myo-
ardial infarction and non–ST-segment elevated myocardial
nfarction; although both represent myocardial infarctions,
heir optimal treatments differ, and investigations target
ach individually. A similar approach is necessary for AHFS.
D physician’s view of AHFS in the ED. With annual
osts estimated at $20.1 billion, HF hospital stays are 1 of
he most expensive U.S. disease expenditures. Because most
HFS admissions are hospitalized via the ED, a system-
ide approach to physiologic success and cost-containment
tarts in the ED. Improving diagnosis, selection of time-
ritical interventions, and disposition will produce down-
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igher likelihood of success, the initial treatment plan is
mportant. The current lack of data and consensus regarding
ppropriate ED diagnosis, treatment goals, and metrics
reates disagreement among caregivers.
Acute heart failure syndrome is a challenging diagnosis,
ecause its dominant symptom of dyspnea is nonspecific,
he physical examination is insensitive (6,7), electrocardio-
rams are inaccurate (8,9), and chest X-ray findings are
nreliable (10–12). Even when diagnostic certainty exists,
vidence-based ED management options are limited, be-
ause few prospective ED interventional AHFS studies have
een conducted. Most ED interventions are based on
istorical or local practices, extrapolating from chronic HF
tudies, or investigations conducted on hospitalized pa-
ients. Thus, early management goals are ill-defined, and
efinitions of “success” are unclear (13).
In suspected AHFS, the principal responsibilities of care
n the ED are, in order of priority: 1) resuscitation;
) identification and initial management of immediate life
hreats; 3) symptom relief; and 4) accurate disposition
sorting those requiring inpatient hospital stay from those
ho might be safely treated and released). The AHFS
isposition decisions are predominantly based on physician
xperience and clinical impressions and involve minimal
bjective data. Among the challenges to disposition are
redicting future intensity of care needs in individual
atients—particularly without objective measures to guide
ecisions—and the multiplicity of options, from discharge
o home; transfer to an OU; or admission to a regular
edical bed, a step-down unit, or an ICU.
The accuracy of these decisions needs be enhanced
hrough development of risk stratification tools. Accurate
dentification of low-risk patients (i.e., those with very low
Figure 1 Risk Stratification Data Points in ED Patients With Su
Note: all superscript numbers relate to the reference numbers 14 to 18. AHFS 
BUN  blood urea nitrogen; Creat  creatinine; ED  emergency department; Na1%] 30-day death or repeat hospital stay rates) would
llow selection of candidates best-suited for early discharge
r OU treatment. Although a comprehensive database of
hronic HF and large registries of hospitalized patients
xist, few identified low-risk patients. Current selection of a
ow-risk cohort is done by exclusion, driven by the absence
f high-risk features and personal experience (Fig. 1)
14–18). Because low-risk patients should have few revisits,
uccessful development of early discharge criteria is essential
or a cost-effective ED-based AHFS program. Outcomes
ssociated with coordinated, multidisciplinary efforts to
chieve a seamless transition to outpatient management
ffer a good prospective study target.
Finally, comorbidities play a large role in initial ED
anagement. Most HF patients have comorbid conditions
hat exacerbate HF or are exacerbated by HF. The ED care
pproach to these patients must incorporate data regarding
otential comorbidities.
ardiologist’s view of acute HF in the ED. Although
ultiple AHFS phenotypes exist, there is no consensus of
efinition (19). Initial triage, treatment, and disposition
ecisions are typically based on the perceived severity of the
resentation. However, long-term risk of any specific phe-
otype is unknown. We need a better understanding of the
atural history of AHFS in patients presenting to the ED to
esign studies to improve outcomes. Thus, a new AHFS
lassification scheme based on pathophysiology, severity,
nd prognosis is critical for both research and clinical
anagement.
Once the diagnosis and phenotype of AHFS have been
stablished and care turned over to the cardiologist or
ospitalist, optimal therapy requires reconciliation of many
ompeting goals. Because the underlying pathophysiology
f HF predicts the probable course and outcomes and
ted Acute Heart Failure
heart failure syndrome; BNP  B-type natriuretic peptide;
ium; SBP  systolic blood pressure.spec
acute
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entation is useful clinically. The 2009 American College of
ardiology/American Heart Association Revised Guide-
ines (1) recognizes 3 types of HF:
. Volume overload; pulmonary and/or systemic conges-
tion, frequently precipitated by an acute increase in
chronic hypertension;
. Profound depression of cardiac output; hypotension,
renal insufficiency, and/or a shock syndrome;
. Combination of 1 and 2.
The severity and tempo of AHFS and comorbidities
mpact management strategies for selecting optimal thera-
ies and the probability of attaining clinical improvement.
hese strategies must also consider long-term prognosis,
atient preferences, and the need to modify therapy during
he clinical course in response to initial interventions. This
ncludes the patient’s hemodynamic stability, the underlying
isease state, comorbidities, prognosis, and the availability
f suitable inpatient resources. Stratifying AHFS patients
y risk of subsequent adverse events is critical to improving
are. High-risk patients should be hospitalized to optimize
ntensity of care (often in an ICU), moderate-risk patients
ight be candidates for OU transfer, and those at low
isk could be discharged from the ED with appropriate
ollow-up.
It is important to take advantage of the “teachable
oment” when an AHFS patient visits the ED or is
ransferred to an inpatient unit. There is a high rate of
ecidivism with many patients not practicing adequate
elf-management. Regardless of where it occurs, improve-
ents in patient and family education and developing tools
o enhance self-management skills are likely to result in
ewer readmissions.
isk Stratification:
apid and Accurate ED Diagnosis
apid, accurate diagnosis of AHFS is vital. Delayed therapy
s associated with increased mortality, as is administration of
HFS treatment to non-AHFS patients (13). Clinical
rediction rules prognostic of short-term fatal and nonfatal
utcomes have been compared (20) and validated (21).
owever, performance of these rules is suboptimal. Two
ational Institutes of Health-sponsored studies, DECIDE
DECIsion making in acute DEcompensated heart failure)
nd STRATIFY (STRATIFYing emergency department
atients with heart failure)—designed to address the chal-
enges of diagnosis and risk stratification—involve the
rospective development of an ED-based risk model that
ncludes variables available during the first 2 h in the ED.
hese consist of medical history, findings on physical
xamination, routine laboratory testing, biomarkers of car-
iac stress and injury, measures of early therapeutic re-
ponse, as well as social and demographic factors. dAlthough natriuretic peptides (NPs) are useful (22,23)
nd cost-effective (24), they have limitations (18,25,26). As
Ps are released in response to myocardial stretch, many
on-HF cardiac stress conditions (e.g., myocardial infarc-
ion) lead to NP elevation. Thus, although a low NP “rules
ut” AHFS, a “rule-in” diagnosis of AHFS by NP is
omplicated by an indeterminate grey zone (27). Addition-
lly, in some AHFS presentations (e.g., flash pulmonary
dema, mitral stenosis) early NP levels might be normal
26). Other confounders include determining whether the
P result represents the patient’s wet or dry weight and that
evels are increased in renal dysfunction but reduced in
besity. Lastly, recent evidence suggests different structural
P forms in “sick” compared with “normal” subjects (28).
Despite these limitations, NPs are strongly prognostic
f future adverse events. The REDHOT (Rapid Emer-
ency Department Heart Failure Outpatient Trial) (29)
howed that the 90-day combined event rate (CHF visits
nd mortality) in patients admitted with B-type NP 200
nd200 pg/ml was 9% and 29%, respectively (p 0.006).
f validated, this NP cutpoint might represent a safe and
ost-effective strategy guiding ED disposition. Other can-
idate markers requiring validation of their prognostic value
nclude mid-regional pro-atrial NP, adrenomedullin,
opeptin, and ST2. Finally, early data suggest that the
nfection marker procalcitonin and pro-atrial NP might
elp differentiate ADHF from pneumonia (30).
Although complex interplay between decreased renal
erfusion and renal congestion might contribute to kidney
ysfunction, the cardiorenal syndrome is a potent AHFS
ortality risk factor (31,32). Although creatinine is tradi-
ionally used to assess renal function, cystatin C is more
ccurate. Sensitive early markers of acute kidney injury, such
s neutrophil gelatinase associated lipocalin, kidney injury
olecule-1, and interleukin-1 (33,34), might also have
linical value. After acute kidney injury, interleukin-1 ex-
ibits a robust rise that precedes other biomarkers. Com-
ined with B-type NP, it might assist in the early detection
f renal dysfunction. Ultimately, a panel of markers for
ardiac stress, infection, necrosis/apoptosis/tissue turnover
e.g., high-sensitivity troponin [17]), and acute kidney
njury might be the most useful in risk stratification,
ssessing both prognosis and guiding management.
Finally, cardiac echocardiography as an ED diagnostic
nd risk stratification tool might be considered. Although
here are few controlled and validated echocardiographic
tudies on the ED evaluation of AHFS—because it is
oninvasive, rapid, and increasingly available—it is an
ttractive technology for future investigations.
D Management of AHFS
o ensure safe, high-quality, and efficient care for AHFS
atients during and after hospital stay, comprehensive
isease management programs—which include patient and
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uch programs might reduce repeat ED visits and hospital
tays. The critical “vulnerable period,” beginning just before
D presentation and extending to a few weeks after
ischarge, is addressed inadequately by traditional ap-
roaches to chronic HF. A personalized AHFS manage-
ent program, initiated in the ED or OU and continued to
fter discharge, provides opportunities for outcome im-
rovement. This strategy should include directed interven-
ion with evidence-based, guideline-recommended thera-
ies for patients with correctable disorders (e.g., ventricular
yssynchrony) (19,35). Conversely, patients at low risk for
hort-term mortality but consuming considerable health
are resources offer a target for “systematic individualized
ondrug, nondevice” management (e.g., disease-specific
ducation, provision of appropriate cost-limited follow-
p, and assistance with transportation or prescription
eeds) (36 –38).
A seamless transition to a personalized disease manage-
ent program beginning in the ED might improve out-
omes. One example might be the OU-based HF model
here low-risk patients receive both brief high-intensity
herapy and social interventions, education, and delineation
f post-discharge care in the ED. Such an approach
mproves short-term outcomes while avoiding in-patient
ospital stay (39). Coupling this strategy with outpatient
ollow-up under the supervision of an HF specialist and
xperienced nurse practitioner might yield additional bene-
ts. This could include the creation of Camp Heart Failure
r day treatment centers in which patients receive infusion
herapy and participate in peer-led support groups. This
trategy, although easily inserted into ED/OU operations,
ould also be incorporated into inpatient post-discharge
are. Prospective research is needed to define the manage-
ent tools for improving outcomes, quality, and costs with
his strategy in selected AHFS phenotypes.
urrent and Future Clinical Trials of AHFS
harmacotherapy. Despite few prospective ED-based tri-
ls of diuretic agents and suggestions of harm with excessive
se, diuretic agents are a mainstay of AHFS treatment.
HLBI’s Heart Failure Network is studying this question
n the DOSE (Diuretic Optimal Strategy Evaluation in
cute Heart Failure) trial. Critically important unanswered
uestions include dose, timing, method of administration,
nd their relative safety in various ED AHFS phenotypes.
his data vacuum exemplifies the challenge that new
harmacologics must meet.
Recent AHFS investigations report different outcomes
etween phase II and III studies. In fact, positive phase III
tudies are extremely rare. One recent example is rolofylline,
here the pilot phase II study (40) showed preservation of
enal function, improvement of dyspnea, and a trend (p 
.055) to decreased 60-day death and cardiac/renal read-
issions. However, the larger follow-up PROTECT-2 dA Study of the Selective A1 Adenosine Receptor Antagonist
W-3902 for Patients Hospitalized With Acute HF and
olume Overload to Assess Treatment Effect on Conges-
ion and Renal Function) trial (41) did not confirm the renal
r death/readmission benefits, although dyspnea improved
hrough the third day.
Many lessons can be learned from these experiences.
hase III trials with neutral outcomes might be underpow-
red by accepting frequently overestimated effects of phase
I data. Enrolling a cohort with excessive phenotypic het-
rogeneity in phase III might also result in divergent
utcomes. Changing standards of care should be accounted
or during trial development and implementation. Trial
esigns frequently overestimate an intervention’s effect,
specially in view of delayed enrollment exposing a patient
o ED standard therapy. Promising (albeit hypothesis-
enerating) beneficial outcome data have been achieved by
ore recent trials, including the phase II Pre-RELAX-
HF (Relaxin for the treatment of patients with acute heart
ailure) study (42). They encouraged enrollment as soon as
ossible after ED presentation. This might enhance the
ikelihood of success by increasing the study’s effect magni-
ude while limiting potential confounding from pre-study
nterventions.
Another research challenge and a fact that complicates
he existing pathophysiologic understanding of AHFS is
oor linkage between symptomatic improvement and major
linical end points improvement. This is illustrated by the
MAC (Vasodilatation in the Management of Acute
HF) study comparing nesiritide and standard care, which
eported reductions in wedge pressure and transient im-
rovements of dyspnea (43). Applying these data to the
ngoing phase IV ASCEND-HF (Double-Blind, Placebo-
ontrolled, Multicenter Acute Study of Clinical Effective-
ess of Nesiritide in Subjects With Decompensated Heart
ailure), required 7,000 patients to evaluate nesiritide’s
otential impact on mortality (44). The enormous cost of
rials designed to demonstrate small improvements in clin-
cal outcome will have to be considered. Nonetheless, in
imilarly large trials the mortality of acute myocardial
nfarction was improved. To achieve benefits in AHFS
anagement, a similar approach might be necessary.
iagnostic and hemodynamic devices. Historically, im-
lanted diagnostic monitoring devices focused on electrophysi-
logic variables. These devices, such as pacemakers, can pro-
ide additional data regarding precipitants of clinical events.
horacic electrical impedance measurements might reflect
linical status and prognosis, because reduced impedance from
xcess lung water is associated with increased wedge pressure
nd longer hospital stays. In the MID-HeFT (Medtronic
mpedance Diagnostics in Heart Failure Patients Trial), an
nverse relationship was shown between thoracic impedance
nd hospital stay. In this study, impedance-derived hemo-
ynamic and physiologic markers (e.g., patient activity)
eclined approximately 2 weeks before hospital stay (45).
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NHLBI Acute Heart Failure Emergency Department Workshop July 27, 2010:343–51mplanted monitors might offer an objective strategy for
esting research targets in ED AHFS evaluation.
Future trials might employ the ED interrogation of
mplantable cardiac-defibrillators, impedance monitors,
nd resynchronization devices to guide clinical care.
hese can record heart rate, rhythm, percentage of atrial
nd ventricular pacing, fluid status, and patient activity
46,47). Potential ED applications might explore the
ssociation of heart rate variability changes in the days
efore hospital stay and the relation of decreased physical
ctivity to admission requirements (46,47). Research
emonstrating that device data accessed in the ED
redict the need for hospital stay or the intensity of
anagement required would be of significant value.
rial Design for AHFS in the ED
he successful ED trial design will require an integrated
pproach that incorporates emergency medicine, cardiology,
aboratory medicine, other clinical stakeholders, as well as
asic research. Prospective studies to define AHFS pheno-
ypes should ideally include an evaluation of cardiac struc-
ure and function at ED presentation (potentially with
chocardiography or other imaging technology). Because
his alone might not be feasible or practical in some ED
ettings, an evaluation of biomarkers to efficiently charac-
erize the pathophysiology, prognosis, and therapeutic re-
ponse in individual patients is needed (48). Comparative
ffectiveness studies of strategies for low-risk AHFS are also
eemed important, especially among patients managed in an
U or followed after an ED encounter in an outpatient
rogram (14,49,50).
AHFS Identified
in the ED
Early
Intervention
Risk-based
Triage
Usual
Triage
Usual care
Assess
Figure 2 Example of a Factorial Design Study With Concurrent
Evaluates the sensitivity of time dependent intervention and the impact of risk-basAlthough not specific to the ED phase of AHFS man-
gement, the clinical value of a multidisciplinary, systems-
ased approach to the transition of care from initial contact
ith the medical system until discharge back to the outpa-
ient environment should be ascertained (51,52). The grow-
ng and evolving use of OU treatment protocols, in which
elatively low-risk AHFS patients or rapid responders to
reatment can be discharged directly from the ED (53),
rovides a unique opportunity to educate patients, initiate
mportant therapies, and organize post-discharge follow-up
nd management (54,55). Within such a construct, the ED
ffers a platform serving as an entry portal to a coordinated
are process that includes the requisite assumption of individ-
al personal responsibility and institutional partnership. There
s also a need to incorporate systematic educational nondrug,
ondevice management (e.g., post-discharge educational inter-
entions, home monitoring) as well investigating the impact of
“dose-dependent” effect of these strategies.
In terms of study methodology, there was a consensus
hat factorial designs (Fig. 2), with concurrent intervention
rms, could offer optimal recruitment and intervention
fficiencies without sacrificing feasibility and potentially
inimizing related costs. Other factors include consider-
tion of ED environmental heterogeneity (e.g., academic vs.
ommunity; urban vs. suburban vs. rural) and the require-
ent of institutional matching. Lastly, there is a need to
onsider ED relevant end points in trials, such as days alive
nd out of hospital, which would be highly generalizable
nd valid in most ED-based studies. A “companion” end
oint, such as the timely application of evidence-based
herapies known to reduce morbidity and mortality, and
notype-
en Care
Non-early
Intervention
Risk-based
Triage
Usual
Triage
oints
vention Arms
ge protocols. Abbreviations as in Figure 1.Phe
Driv
 End-P
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iomarkers reflective of these processes, might also be
ppropriate.
uthor Disclosures
r. Peacock has received research support from Abbott,
eckman-Coulter, Biosite, Brahms, Heartscape, EKR, and
he Medicines Co.; has received honoraria from Abbott,
eckman-Coulter, Biosite, EKR, and The Medicines Co.;
nd owns stock in Vital Sensors. Dr. Braunwald has
eceived research support from Merck and Co., Inc., No-
artis, and Roche Diagnostics Corp., and honoraria from
erck and Co. Dr. Abraham has received research support
rom Medtronic, Inc., Paracor, Inc., and St. Jude Medical,
nd honoraria from Medtronic, Inc., Respironics, St. Jude
edical, ARCA BioPharm, BioEnergy, Biotronik, Capri-
or, Cardiac Concepts, CardioKine, CardioKinetix, Inc.,
ardioMEMS, Edwards Lifesciences, and Paracor Inc. Dr.
lbert has received honoraria from GlaxoSmithKline,
edtronic, Merck, and Impedance Cardiology Systems,
nc. Dr. Burnett has received research support from Bayer,
erck, Nile Therapeutics, BioRad, Trevena, and Anexon;
onoraria from Nile Therapeutics, Otsuka, and Anexon;
nd royalties from Nile Therapeutics and Anexon. Dr.
hristenson has received research support from Siemens
ealthcare Diagnostics, Roche Diagnostics, BG Medicine,
nd Critical Care Diagnostics, and honoraria from Siemens.
r. Collins has received research support from Biosignetics,
novise Medical, Inc., Abbott Point-of-Care, Corthera, and
rahms, and honoraria from Abbott Point-of-Care, PDL
ioPharma, Astellas, Otsuka Pharmaceuticals, The Medi-
ines Co., and Corthera. Dr. Fonarow has received hono-
aria from Novartis, Medtronic, Scios, GlaxoSmith-
line, Pfizer, and Merck. Dr. Gheorghiade has received
onoraria from Abbott Labs, Astellas, Astra Zeneca, Bayer
chering Pharma AG, CorThera, Inc., Cytokinetics, Inc.,
ebioPharm S.A., Errekappa Terapeutici (Milan, Italy),
laxoSmithKline, Ikaria, Johnson & Johnson, Med-
ronic, Merck, Novartis Pharma AG, Otsuka Pharmaceu-
icals, Palatin Technologies, Pericor Therapeutics, Protein
esign Laboratories, Sanofi-Aventis, Sigma Tau, Solvay
harmaceuticals, and Trevena Therapeutics. Dr. Hollander
as received research support from Siemens Diagnostics,
rahms, Nanosphere, and Biosite/Inverness, and honoraria
rom Sanofi-Aventis and Bristol-Myers Squibb. Dr. Kirk
as received honoraria from Sanofi-Aventis, Otsuka, and
iosite. Dr. Levy has received research support from
laxoSmithKline, The Cleveland Clinic Foundation,
stellas Pharma US, Inc., Solvay Pharmaceuticals, Cor-
hera, Inc., Nile Therapeutics, Inc., Biosite, Inc., Cardio-
ynamics, Inc., and Inovise Medical, and honoraria from
he Medicines Co. Dr. Maisel has received research
upport from Inverness, Brahms, Critical Diagnostics,
bbott, and Nanosphere, and honoraria from Inverness. Dr.
assie has received honoraria from Merck-Novacardia, Cor-hera, Cytokinetics, Novartis, Nile Therapeutics, and Boston
cientific Co. Dr. O’Connor has received research support
rom Johnson & Johnson, Merck, Forest, Medtronic, and
oche Diagnostics, and honoraria from Johnson & Johnson,
erck, Forest, Medtronic, and Roche Diagnostics. Dr.
ang has received research support from Merck and PDL
ioPharma, and honoraria from Astellas, Bayer, EKR
herapeutics, Johnson & Johnson, The Medicines Co.,
tsuka, Palatin Technologies, PDL BioPharma, Pericor
herapeutics, Solvay, BiogenIdec, Corthera, Ikaria, and
ile Therapeutics. Dr. Stevenson has received honoraria
rom Medtronics, Inc. Dr. Storrow has received research
upport from Biosignetics, PDL BioPharma, Abbott Diag-
ostics, and Meso Scale Discovery, and honoraria from
bbott Diagnostics, Ortho-Clinical Diagnostics, and
anofi-Aventis. Dr. Teerlink has received research support
nd honoraria from Abbott/Orion, Actelion, Amgen, As-
ellas, AstraZeneca, BAS Medical/Corthera, Biogen Idec,
ristol-Myers Squibb, Cardio-Dynamics, Cardioxyl, CHF
olutions, CoGeneSys/Teva, Cytokinetics, Geron, Glaxo-
mithKline, Medtronic, Momentum Research, National In-
titutes of Health, NovaCardia/Merck, Novartis, Protein De-
ign Labs, Relypsa, Sanofi-Aventis, Scios/Johnson & Johnson,
nd Zealand Pharma.
eprint requests and correspondence: Dr. W. Frank Peacock,
esk E-19, Emergency Medicine Institute, The Cleveland Clinic,
500 Euclid Avenue, Cleveland, Ohio 44195. E-mail: Peacocw@
cf.org.
EFERENCES
1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update
incorporated into the ACC/AHA 2005 guidelines for the diagnosis
and management of heart failure in adults: a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol 2009;53:e1–90.
2. Adams KF Jr., Fonarow GC, Emerman CL, et al., ADHERE
Scientific Advisory Committee and Investigators. Characteristics and
outcomes of patients hospitalized for heart failure in the United States:
rationale, design, and preliminary observations from the first 100,000
cases in the Acute Decompensated Heart Failure National Registry
(ADHERE). Am Heart J 2005;149:209–16.
3. ADHERE Scientific Advisory Committee. Acute Decompensated
Heart Failure National Registry (ADHERE) Core Module Q1 2006
Final Cumulative National Benchmark Report. Mountain View, CA:
Scios, Inc., 2006.
4. Gheorghiade M, Abraham WT, Albert NM, et al., OPTIMIZE–HF
Investigators and Coordinators. Systolic blood pressure at admission,
clinical characteristics, and outcomes in patients hospitalized with
acute heart failure. JAMA 2006;296:2259–60.
5. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and
stroke statistics—2009 update: a report from the American Heart
Association Statistics Committee and Stroke Statistics Subcommittee.
Circulation 2009;119:e21–181.
6. Stevenson LW, Perloff JK. The limited reliability of physical signs for
estimating hemodynamics in chronic heart. JAMA 1989;26:884–8.
7. Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination
diagnose left-sided heart failure in adults? JAMA 1997;277:1712–9.
8. Davie AP, Francis CM, Love MP, et al. Value of the electrocardio-
gram in identifying heart failure due to left ventricular systolic
dysfunction. BMJ 1996;312:1161.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
350 Peacock et al. JACC Vol. 56, No. 5, 2010
NHLBI Acute Heart Failure Emergency Department Workshop July 27, 2010:343–519. Gillespie ND, McNeill G, Pringle T, Ogston S, Struthers AD, Pringle SD.
Cross sectional study of contribution of clinical assessment and simple
cardiac investigations to diagnosis of left ventricular systolic dysfunction in
patients admitted with acute dyspnoea. BMJ 1997;315:604.
0. Badgett RG, Mulrow CD, Otto PM, Ramirez G. How well can the
chest radiograph diagnose left ventricular dysfunction? J Gen Intern
Med 1996;11:625–34.
1. Collins SP, Lindsell CJ, Storrow AB, Abraham WT, ADHERE
Scientific Advisory Committee, Investigators and Study Group. Prev-
alence of negative chest radiography results in the emergency depart-
ment patient with decompensated heart failure. Ann Emerg Med
2006;47:19–21.
2. Turnipseed SD, Bair AE, Kirk JD, Diercks DB, Tabar P, Amsterdam
EA. Electrocardiogram differentiation of benign early repolarization
versus acute myocardial infarction by emergency physicians and car-
diologists. Acad Emerg Med 2006;13:961–6.
3. Peacock WF, Fonarow GC, Ander DS, et al. Society of Chest Pain
Centers recommendations for the evaluation and management of the
observation stay acute heart failure patient—parts 1–6. Acute Card
Care 2009;11:3–42.
4. Diercks DB, Peacock WF, Kirk JD, Weber JE. ED patients with heart
failure: identification of an observational unit-appropriate cohort.
Am J Emerg Med 2006;24:319–24.
5. Burkhardt J, Peacock WF, Emerman CL. Predictors of emergency
department observation unit outcomes. Acad Emerg Med 2005;12:
869–74.
6. Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ,
for the ADHERE Scientific Advisory Committee, Study Group, and
Investigators. Risk stratification for in-hospital mortality in acutely
decompensated heart failure: classification and regression tree analysis.
JAMA 2005;293:572–80.
7. Peacock WF IV, De Marco T, Fonarow GC, et al., ADHERE
Investigators. Cardiac troponin and outcome in acute heart failure.
N Engl J Med 2008;358:2117–26.
8. Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type
natriuretic peptide and cardiac troponin levels to predict in-hospital
mortality from ADHERE. Am J Cardiol 2008;101:231–7.
9. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll
Cardiol 2009;53:557–73.
0. Auble TE, Hsieh M, McCausland JB, Yealy DM. Comparison of four
clinical prediction rules for estimating risk in heart failure. Ann Emerg
Med 2007;50:127–35.
1. Hsieh M, Auble TE, Yealy DM. Validation of the Acute Heart
Failure Index. Ann Emerg Med 2008;51:37–44.
2. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement
of B-type natriuretic peptide in the emergency diagnosis of heart
failure. N Engl J Med 2002;347:161–7.
3. Januzzi JL Jr., Camargo CA, Anwaruddin S, et al. The N-terminal
pro-BNP investigation of dyspnea in the emergency department
(PRIDE) study. Am J Cardiol 2005;95:948–54.
4. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic
peptide in the evaluation and management of acute dyspnea. N Engl
J Med 2004;350:647–54.
5. Peacock WF, Mueller C, Disomma S, Maisel A. Emergency depart-
ment perspectives on B-type natriuretic peptide utility. Congest Heart
Fail 2008;14 Suppl 1:17–20.
6. Tang WH, Francis GS, Morrow DA, et al., NACB Committee.
National Academy of Clinical Biochemistry Laboratory Medicine
Practice Guidelines: clinical utilization of cardiac biomarker testing in
heart failure. Clin Biochem 2008;41:210–21.
7. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic
peptide and clinical judgment in emergency diagnosis of heart failure:
analysis from Breathing Not Properly (BNP) Multinational Study.
Circulation 2002;106:416–22.
8. Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett
JC Jr., Muddiman DC. Quantitative mass spectral evidence for the
absence of circulating brain natriuretic peptide (BNP-32) in severe
human heart failure. Proc Natl Acad Sci U S A 2005;102:17442–7.
9. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid
Emergency Department Heart Failure Outpatient Trial (REDHOT).
A multicenter study of B-type natriuretic peptide levels, emergency
department decision making, and outcomes in patients presenting with
shortness of breath. J Am Coll Cardiol 2004;44:1328–33.
50. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone
markers for diagnosis and prognosis in acute dyspnea: results from the
BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol
2010;55:2062–76.
1. deFilippi CR, Seliger SL, Maynard S, Christenson RH. Impact of
renal disease on natriuretic peptide testing for diagnosing decompen-
sated heart failure and predicting mortality. Clin Chem 2007;53:
1511–9.
2. van Kimmenade RR, Januzzi JL Jr., Baggish AL, et al. Amino-
terminal pro-brain natriuretic peptide, renal function, and outcomes in
acute heart failure: redefining the cardiorenal interaction? J Am Coll
Cardiol 2006;48:1621–7.
3. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL.
Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker
of tubular damage, is increased in patients with chronic heart failure.
Eur J Heart Fail 2008;10:997–1000.
4. Gupta S, Drazner MH, de Lemos JA. Newer biomarkers in heart
failure. Heart Fail Clin 2009;5:579–88.
5. Chung AK, Pang PS, Fonarow GC, Gheorghiade M. Acute heart
failure syndromes: potential strategies to improve post-discharge
outcomes. Curr Treat Options Cardiovasc Med 2008;10:349–57.
6. Horowitz CR, Rein SB, Leventhal H. A story of maladies, miscon-
ceptions and mishaps: effective management of heart failure. Soc Sci
Med 2004;58:631–43.
7. Friedmann E, Thomas SA, Liu F, Morton PG, Chapa D, Gottlieb
SS, Sudden Cardiac Death in Heart Failure Trial Investigators.
Relationship of depression, anxiety, and social isolation to chronic
heart failure outpatient mortality. Am Heart J 2006;152:940.e1–8.
8. Kollipara UK, Jaffer O, Amin A, et al. Relation of lack of knowledge
about dietary sodium to hospital readmission in patients with heart
failure. Am J Cardiol 2008;102:1212–5.
9. Peacock WF IV, Remer EE, Aponte J, Moffa DA, Emerman CE,
Albert NM. Effective observation unit treatment of decompensated
heart failure. Congest Heart Fail 2002;8:68–73.
0. Cotter G, Dittrich H, Davison Weatherley B, et al. The PROTECT
pilot study: a randomized, placebo-controlled, dose finding study of
the adenosine A1 receptor antagonist rolofylline in patients with acute
heart failure and renal impairment. J Card Fail 2008;14:631–40.
1. Cleland JG, Coletta AP, Yassin A, Buga L, Torabi A, Clark AL.
Clinical trials update from the European Society of Cardiology
Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European
CRT survey, German pre-SCD II registry, and MADIT-CRT. Eur
J Heart Fail 2009;11:1214–9.
2. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of
patients with acute heart failure (Pre-RELAX-AHF): a multicentre,
randomised, placebo-controlled, parallel-group, dose-finding phase
IIb study. Lancet 2009;373:1429–39.
3. Publication Committee for the VMAC Investigators (Vasodilatation
in the Management of Acute CHF). Intravenous nesiritide vs nitro-
glycerin for treatment of decompensated congestive heart failure: a
randomized controlled trial. JAMA 2002;287:1531–40.
4. Hernandez AF, O‘Connor CM, Starling RC, et al. Rationale and
design of the Acute Study of Clinical Effectiveness of Nesiritide in
Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J
2009;157:271–7.
5. Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring
in patients with heart failure correlation with fluid status and feasibility
of early warning preceding hospitalization. Circulation 2005;112:
841–8.
6. Poulsen SH, Jensen SE, Moller JE, Egstrup K. Prognostic value of left
ventricular diastolic function and association with heart rate variability
after a first acute myocardial infarction. Heart 2001;86:376–80.
7. Landolina M, Gasparini M, Lunati M, et al. Heart rate variability
monitored by the implanted device predicts response to CRT and
long-term clinical outcome in patients with advanced heart failure. Eur
J Heart Fail 2008;10:1073–9.
8. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:
2148–59.
9. Collins SP, Lindsell CJ, Naftilan AJ, et al. Low-risk acute heart failure
patients: external validation of the Society of Chest Pain Center‘s
recommendations. Crit Pathw Cardiol 2009;8:99–103.0. Collins SP, Storrow AB. Acute heart failure risk stratification: can we
define low risk? Heart Fail Clin 2009;5:75–83, vii.
55
5
5
5
351JACC Vol. 56, No. 5, 2010 Peacock et al.
July 27, 2010:343–51 NHLBI Acute Heart Failure Emergency Department Workshop1. Naylor MD, Brooten D, Campbell R, et al. Comprehensive discharge
planning and home follow-up of hospitalized elders: a randomized
clinical trial. JAMA 1999;281:613–20.
2. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE,
Carney RM. A multidisciplinary intervention to prevent the readmis-
sion of elderly patients with congestive heart failure. N Engl J Med
1995;333:1190–5.
3. Hsieh M, Auble TE, Yealy DM. Evidence-based emergency medi-
cine. Predicting the future: can this patient with acute congestive heart
failure be safely discharged from the emergency department? Ann
Emerg Med 2002;39:181–9. K4. Storrow AB, Collins SP, Lyons MS, Wagoner LE, Gibler WB,
Lindsell CJ. Emergency department observation of heart failure:
preliminary analysis of safety and cost. Congest Heart Fail 2005;11:
68–72.
5. Peacock WF, Young J, Collins S, Diercks D, Emerman C. Heart
failure observation units: optimizing care. Ann Emerg Med 2006;47:
22–33.ey Words: emergency medicine y heart failure y research.
